## Annex H. Indicative non-binding estimated quantities

Table $\mathrm{n}^{\circ}$ 1. Total estimated quantities of bedaquiline 100 mg to be procured via GDF in basic units (tablets) for the period 15 August 2023 to 31 December 2024 per category of demand:


* For detailed product specifications please refer to Annex B of the ITB document.
** Originator and generics

Table $n^{\circ}$ 2. Projection of the quantities of bedaquiline 100 mg likely to be procured via GDF per quarter for Schedules 4 and 5 for the total estimated quantities (in Table $\mathrm{n}^{\circ} 1$ ).

| Schedule number and <br> name | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 |
| :--- | :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Estimated quantities to be procured via GDF (in basic units, tablets) |  |  |  |  |  |
| Schedule 4: Bedaquiline <br> 100mg demand for all <br> suppliers | 1000000 | 400000 | 2500000 | 2300000 | 500000 | 300000 |
| Schedule 5: Bedaquiline <br> 100mg demand for <br> originator product only | 2000000 | 0 | 1500000 | 0 | 500000 | 0 |

This information is based on the best available information at the time of the tender publication. This information is provided for planning purposes only. Actual procurement may not align with these projections. These projections do not bind GDF to any procurement.

Table n³. Potential additional quantities of bedaquiline 100mg for the period 15 August 2023 to 31 December 2024, which may or may not be procured through GDF based on country decision.

| Category of demand | Estimated quantities <br> (in basic units, tablets) |
| :--- | ---: |
| Potential additional quantities of bedaquiline 100 mg for <br> all suppliers | $\mathbf{1 1 5 0 0 0 0 0}$ |
| Potential additional quantities of bedaquiline 100 mg for <br> originator product only | $\mathbf{5 5 0 0} 000$ |

